Overview
flowchart TD
CDKL5["CDKL5"] -->|"activates"| Als["Als"]
CDKL5["CDKL5"] -->|"associated with"| HCN1["HCN1"]
CDKL5["CDKL5"] -->|"associated with"| KCNQ2["KCNQ2"]
CDKL5["CDKL5"] -->|"associated with"| PLCB1["PLCB1"]
CDKL5["CDKL5"] -->|"associated with"| SCN1A["SCN1A"]
CDKL5["CDKL5"] -->|"associated with"| SCN2A["SCN2A"]
CDKL5["CDKL5"] -->|"associated with"| SCN8A["SCN8A"]
CDKL5["CDKL5"] -->|"associated with"| STXBP1["STXBP1"]
CDKL5["CDKL5"] -->|"associated with"| WWOX["WWOX"]
CDKL5["CDKL5"] -->|"activates"| ERK["ERK"]
CDKL5["CDKL5"] -->|"activates"| Neurogenesis["Neurogenesis"]
CDKL5["CDKL5"] -->|"activates"| Apoptosis["Apoptosis"]
CDKL5["CDKL5"] -->|"participates in"| autophagy_pathway["autophagy pathway"]
GENES["GENES"] -->|"contributes to"| CDKL5["CDKL5"]
style CDKL5 fill:#4fc3f7,stroke:#333,color:#000
The CDKL5 Alliance is an international non-profit organization dedicated to accelerating the development of treatments and ultimately a cure for [CDKL5 deficiency disorder](/diseases/cdkl5-deficiency-disorder) (CDD), a rare X-linked developmental and epileptic encephalopathy caused by variants in the [CDKL5](/entities/cdkl5) gene. Founded by parents of children with CDKL5 variants, the Alliance serves as the primary global patient advocacy organization for the CDKL5 community, funding research, supporting clinical trials, connecting families, and advocating for regulatory policies that accelerate therapy development.
Mission
...Overview
Mermaid diagram (expand to render)
The CDKL5 Alliance is an international non-profit organization dedicated to accelerating the development of treatments and ultimately a cure for [CDKL5 deficiency disorder](/diseases/cdkl5-deficiency-disorder) (CDD), a rare X-linked developmental and epileptic encephalopathy caused by variants in the [CDKL5](/entities/cdkl5) gene. Founded by parents of children with CDKL5 variants, the Alliance serves as the primary global patient advocacy organization for the CDKL5 community, funding research, supporting clinical trials, connecting families, and advocating for regulatory policies that accelerate therapy development.
Mission
To drive the development of effective treatments and a cure for CDKL5 deficiency disorder by funding innovative research, facilitating clinical trials, providing comprehensive family support, and advocating for regulatory policies that enable rapid therapy development and global access.
History
The CDKL5 Alliance was established through the merger of multiple regional CDKL5 organizations to create a unified global voice for the CDKL5 community:
- CDKL5 Foundation (US): Founded in 2012, initially focused on family support and research funding
- CDKL5 UK: Established 2014, focused on UK-specific support and research advocacy
- Lega Italiana CDKL5: Italian organization supporting families and research
- Alliance Formation: The global CDKL5 Alliance was formed in 2022 to coordinate international efforts
Key Activities
Research Funding
The CDKL5 Alliance is the primary non-governmental funder of CDKL5-specific research globally:
- Annual research grants: Competitive grant cycles supporting basic science, translational, and clinical research on CDKL5 deficiency disorder. Priority areas include:
- Gene therapy approaches (AAV-CDKL5)
- Antisense oligonucleotide (ASO) development
- Small molecule modulators and repurposing
- Biomarker identification and validation
- Natural history studies and endpoint development
- Natural history study support: Funding and patient recruitment for international CDKL5 natural history registries that are critical for clinical trial design and regulatory submissions
- Preclinical consortium: Collaborative programs that share data, animal models, and resources across academic labs working on CDKL5
- iPSC bank: Support for creation and distribution of CDKL5 patient-derived induced pluripotent stem cell lines for research
Clinical Trial Support
The Alliance plays a critical role in connecting patients with clinical trials and therapy development:
- Trial matching: Direct patient-to-trial referrals through the Alliance's patient registry and family matching services
- Site identification: Working with companies to identify suitable clinical trial sites with CDKL5 expertise
- Patient education: Informing families about trial eligibility, risks, and expectations through webinars, conferences, and educational materials
- Industry partnerships: Facilitating partnerships between academia and industry for CDKL5 therapy development
- Regulatory engagement: Active engagement with FDA, EMA, and other regulatory agencies to advocate for accelerated approval pathways
Patient and Family Support
- Family conferences: Annual international family conference bringing together patients, families, researchers, and industry representatives
- Family support programs: Emergency funds, equipment assistance, and family connection programs
- Registry: International patient registry with genetic data, clinical information, and longitudinal follow-up enabling research recruitment
- Online communities: Active online communities connecting families for peer support and information sharing across multiple platforms
- Regional coordinators: Local family liaisons in North America, Europe, Asia-Pacific, and Latin America
Regulatory Advocacy
The Alliance engages actively with regulatory agencies worldwide:
- FDA engagement: Participation in FDA Patient-Focused Drug Development meetings, regulatory workshops, and orphan drug designation processes
- Orphan drug designation: Supporting companies seeking orphan drug designation and rare pediatric disease priority review vouchers
- Accelerated approval pathways: Advocating for regulatory frameworks that enable faster access to transformative therapies based on natural history data and surrogate endpoints
- International harmonization: Working with international regulatory counterparts on harmonized approaches for rare epilepsy therapies
CDKL5 Therapeutic Pipeline
The Alliance has helped catalyze a growing therapeutic pipeline for CDKL5 deficiency disorder:
| Program | Type | Stage | Developer |
|---------|------|-------|-----------|
| AAV-CDKL5 | Gene replacement | Preclinical | Vigonvita Sciences |
| CDKL5 ASO | Splice modulation | Discovery | Various academic groups |
| CDKL5 kinase activators | Small molecule | Preclinical | Multiple pharma |
| Gene therapy (ICM) | AAV-CDKL5 | Preclinical | Academic (multiple) |
Key Programs to Watch
Vigonvita Sciences (China): AAV-based CDKL5 gene therapy in IND-enabling studies, with planned IND filing in 2026
Academic programs: Multiple academic groups at US and European institutions working on CDKL5 gene therapy and ASO approaches
Repurposing screens: Drug repurposing screens have identified potential kinase modulators under investigationNatural History Studies
International CDKL5 Natural History Study
The Alliance supports the primary natural history study for CDKL5 deficiency disorder:
- Sponsor: CDKL5 Alliance in partnership with academic medical centers
- Cohort: N=150+ patients with confirmed CDKL5 variants
- Endpoints: Seizure trajectory, developmental outcomes, EEG patterns, motor function, visual impairment progression
- Status: Ongoing, recruitment open globally
- Regulatory value: Natural history data used as external comparator for single-arm trial designs, supporting accelerated approval pathways
Published Natural History Data
The Alliance has supported publication of key natural history findings:
- Long-term seizure outcomes in CDKL5 deficiency disorder
- Developmental trajectory studies establishing baseline expectations
- EEG pattern evolution and correlation with clinical outcomes
- Cortical visual impairment natural history
Family Resources
Diagnostic Support
- Diagnostic guidance: Information for families navigating the diagnostic process
- Genetic counseling: Resources for understanding CDKL5 inheritance patterns and family planning
- Newly diagnosed packets: Comprehensive information packages for newly diagnosed families
Care Resources
- Medical guidelines: Consensus-based care recommendations for CDKL5 deficiency disorder
- Therapy guides: Information about available therapies including physical, occupational, speech, and behavioral interventions
- Seizure management: Guidelines for seizure types common in CDD, including rescue medication protocols
- GI and feeding: Resources for managing gastrointestinal complications common in CDKL5 patients
- Sleep resources: Guidance for addressing sleep disturbances common in CDD
Educational Materials
- School accommodations: Information about IEPs, 504 plans, and educational interventions
- Transition planning: Resources for adolescents and young adults moving to adult care
Research Priorities
The Alliance has identified key therapeutic targets and research priorities:
CDKL5 gene replacement: AAV-delivered CDKL5 to restore functional protein expression
ASO approaches: Antisense oligonucleotides to modulate CDKL5 splicing or expression
Small molecule modulators: Kinase activators or channel modulators to improve neuronal function
Biomarker development: Quantitative biomarkers for endpoint measurement and patient stratification
Natural history: Continued natural history data collection to support regulatory submissionsCompetitive Landscape
The CDKL5 therapy field is advancing, with the Alliance playing a central coordinating role:
| Program | Company/Group | Modality | Phase |
|--------|---------------|----------|-------|
| AAV-CDKL5 | Vigonvita Sciences | Gene therapy | Preclinical (IND-enabling) |
| AAV-CDKL5 | Multiple academic groups | Gene therapy | Preclinical |
| CDKL5 ASO | Various academic | Splice modulation | Discovery |
| Kinase modulators | Various | Small molecule | Preclinical |
Global Reach
The CDKL5 Alliance coordinates efforts across multiple regions:
- North America: US and Canada family support and research coordination
- Europe: UK, Germany, France, Italy, Spain, and Nordic countries
- Asia-Pacific: Australia, Japan, and other Asia-Pacific regions
- Latin America: Growing family community in Brazil, Mexico, and Argentina
Funding and Financials
The Alliance funds its mission through:
- Individual donations: Family and community donations
- Foundation grants: Support from private foundations
- Corporate partnerships: Industry sponsorship for research and events
- Event fundraising: Annual galas, walks, and awareness campaigns
All research grants are awarded through a competitive peer-review process with external scientific review.
How to Get Involved
For Families
- Join the CDKL5 Alliance patient registry
- Attend annual family conferences
- Connect with regional family coordinators
- Participate in natural history studies
For Researchers
- Apply for research grants through annual grant cycles
- Access the CDKL5 iPSC bank and animal models
- Collaborate through the preclinical consortium
For Industry
- Partner on clinical trial design and site selection
- Access patient registry for recruitment support
- Engage with regulatory advocacy initiatives
References
[CDKL5 Alliance Official Website](https://www.cdkl5alliance.org)
[CDKL5 Deficiency Disorder Disease Page](/diseases/cdkl5-deficiency-disorder)
[CDKL5 Gene Page](/entities/cdkl5)
[Vigonvita CDKL5 Program](/clinical-trials/vigonvita-cdkl5-deficiency-preclinical)
[Vigonvita Sciences Company Page](/companies/vigonvita-sciences)Pathway Diagram
The following diagram shows the key molecular relationships involving CDKL5 Alliance discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)